| scholarly article | Q13442814 |
| P50 | author | Stuart T. Nichol | Q60415973 |
| Jonathan S Towner | Q87983083 | ||
| John W. Huggins | Q113070223 | ||
| P2093 | author name string | Cynthia S Goldsmith | |
| Jason Paragas | |||
| Manisha Gupta | |||
| Jason E Dover | |||
| P2860 | cites work | Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. | Q33823630 |
| 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice | Q33959778 | ||
| Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys | Q33974706 | ||
| Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model | Q34068520 | ||
| Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans | Q34230933 | ||
| Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture | Q34326549 | ||
| Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome | Q37093682 | ||
| Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus | Q38355197 | ||
| Infection and activation of monocytes by Marburg and Ebola viruses | Q39605104 | ||
| A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus | Q40538104 | ||
| Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection | Q40552244 | ||
| Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. | Q40602946 | ||
| Ebola virus defective interfering particles and persistent infection | Q40632676 | ||
| Pathogenesis of experimental Ebola virus infection in guinea pigs | Q44089764 | ||
| A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever | Q44089779 | ||
| Elucidation of Nipah virus morphogenesis and replication using ultrastructural and molecular approaches | Q45728992 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zaire ebolavirus | Q8064876 |
| drug screening | Q10505555 | ||
| urban ecology | Q1430301 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 20-27 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Virology | Q7934867 |
| P1476 | title | Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening | |
| P478 | volume | 332 |
| Q40070709 | A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. |
| Q34665879 | A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. |
| Q34999859 | A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses |
| Q37209733 | A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals |
| Q34042685 | A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. |
| Q30588041 | A novel porcine reproductive and respiratory syndrome virus vector system that stably expresses enhanced green fluorescent protein as a separate transcription unit |
| Q43106551 | A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays |
| Q46247452 | A review on the antagonist Ebola: A prophylactic approach. |
| Q30279239 | A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity |
| Q36040533 | Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses |
| Q37252982 | An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions |
| Q60193415 | An emergent Ebola virus nucleoprotein variant influences virion budding, oligomerization, transcription and replication |
| Q89548894 | Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization |
| Q58779740 | Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors |
| Q37728345 | Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection |
| Q33538454 | Antiviral activity of a small-molecule inhibitor of filovirus infection |
| Q26750838 | Applications of Replicating-Competent Reporter-Expressing Viruses in Diagnostic and Molecular Virology |
| Q54218743 | Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. |
| Q37190830 | Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection |
| Q36736403 | Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies |
| Q40295821 | Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor |
| Q40243605 | Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway |
| Q36522002 | Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection |
| Q64106080 | Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk |
| Q37690397 | Development and application of reporter-expressing mononegaviruses: current challenges and perspectives |
| Q40149516 | Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein |
| Q42266175 | Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate |
| Q40353545 | Development of high-content imaging assays for lethal viral pathogens. |
| Q36379341 | Development of treatment strategies to combat Ebola and Marburg viruses |
| Q40105589 | Discovery of a Broad-Spectrum Antiviral Compound That Inhibits Pyrimidine Biosynthesis and Establishes a Type 1 Interferon-Independent Antiviral State |
| Q57028377 | Disruption of Phosphatidylserine Synthesis or Trafficking Reduces Infectivity of Ebola Virus |
| Q59352107 | Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule |
| Q34274569 | Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses |
| Q61805800 | Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads |
| Q41676229 | Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. |
| Q59355029 | Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation |
| Q57059911 | Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies |
| Q36827365 | Ebola virus does not block apoptotic signaling pathways. |
| Q33758034 | Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection |
| Q40454256 | Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. |
| Q24301618 | Ebola virus uses clathrin-mediated endocytosis as an entry pathway |
| Q40287482 | Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection |
| Q35601783 | Evaluation of perceived threat differences posed by filovirus variants |
| Q28554599 | Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus |
| Q35038226 | Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics |
| Q24568225 | FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. |
| Q27490384 | FGI-104: a broad-spectrum small molecule inhibitor of viral infection |
| Q34375243 | Filovirus replication and transcription |
| Q40066603 | GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses |
| Q40054473 | Generation of Recombinant Ebola Viruses Using Reverse Genetics |
| Q60031608 | High Throughput and Computational Repurposing for Neglected Diseases |
| Q47550612 | High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test |
| Q35748556 | High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication |
| Q38287391 | Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. |
| Q42021625 | Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP). |
| Q39177100 | Identification of a broad-spectrum inhibitor of viral RNA synthesis: validation of a prototype virus-based approach |
| Q33712786 | Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening |
| Q40256077 | Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry |
| Q27681581 | In Silico Derived Small Molecules Bind the Filovirus VP35 Protein and Inhibit Its Polymerase Cofactor Activity |
| Q34717930 | Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. |
| Q24294470 | Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin |
| Q36484103 | Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus |
| Q28281834 | Inhibition of heat-shock protein 90 reduces Ebola virus replication |
| Q38719410 | Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions |
| Q28550929 | Interferon-γ Inhibits Ebola Virus Infection |
| Q34519919 | In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses |
| Q21090770 | Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors |
| Q40054463 | Luciferase-Expressing Ebolaviruses as Tools for Screening of Antivirals |
| Q35132756 | Mechanism of human antibody-mediated neutralization of Marburg virus |
| Q36650409 | Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses |
| Q90554819 | Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials |
| Q24696012 | Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia |
| Q56897586 | Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein |
| Q28486226 | Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection |
| Q40471665 | Permeabilization of the plasma membrane by Ebola virus GP2. |
| Q37168685 | Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication |
| Q35121478 | Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA |
| Q30230272 | Progress towards the treatment of Ebola haemorrhagic fever |
| Q57167222 | Protein Phosphatase 1-Targeting Small-Molecule C31 Inhibits Ebola Virus Replication |
| Q24562099 | Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells |
| Q35557172 | Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread |
| Q28387786 | Replication-competent fluorescent-expressing influenza B virus |
| Q92734169 | Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111 |
| Q34301750 | Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30 |
| Q34342378 | Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire. |
| Q58588686 | Reverse Genetic Approaches for the Generation of Recombinant Zika Virus |
| Q40056806 | Reverse Genetics Systems for Filoviruses |
| Q41936032 | Reverse Genetics of Filoviruses |
| Q34717075 | Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication |
| Q38244444 | Reverse genetics systems as tools for the development of novel therapies against filoviruses |
| Q35641426 | Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry |
| Q56982857 | Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions |
| Q34044597 | Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription |
| Q37036794 | Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. |
| Q24329155 | Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection |
| Q57291140 | Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis |
| Q51782676 | Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs. |
| Q34971349 | Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies |
| Q90401053 | Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition |
| Q52724948 | Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. |
| Q36216308 | The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. |
| Q34042182 | The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus |
| Q36085668 | The evolving field of biodefence: therapeutic developments and diagnostics |
| Q36978855 | The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains |
| Q34516555 | Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys |
| Q92154130 | Therapeutic strategies to target the Ebola virus life cycle |
| Q88978790 | Topoisomerase III-beta is required for efficient replication of positive-sense RNA viruses |
| Q33568288 | Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA |
| Q38610343 | Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein |
Search more.